A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

July 31, 2016

Conditions
Tardive Dyskinesia
Interventions
DRUG

NBI-98854

NBI-98854 40 mg capsules

DRUG

Placebo

NBI-98854 placebo capsules

Trial Locations (54)

Unknown

Little Rock

Anaheim

Glendale

Irvine

Long Beach

Los Angeles

National City

Norwalk

Oakland

Oceanside

San Bernardino

San Diego

Torrance

Bradenton

Hialeah

Kissimmee

Leesburg

Maitland

Miami

North Miami

Chicago

Oak Brook

Shreveport

Baltimore

Glen Burnie

Worcester

Flowood

St Louis

Lincoln

Amherst

Cedarhurst

Rochester

Durham

Pinehurst

Dayton

Shaker Heights

Oklahoma City

Conshohocken

Norristown

Phoenixville

Scranton

Charleston

Memphis

DeSoto

Fort Worth

Irving

Petersburg

Spokane

Vancouver

London

Toronto

Montreal

Caguas

San Juan

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY